Prevalence of chronic pain in a metropolitan area of a developing country: a population-based study.

OBJECTIVE: To estimate the prevalence of chronic pain (CP) in the adult population living in the city of São Paulo, Brazil, and to identify factors associated with CP in developing countries. METHODS: A cross-sectional study using a computer-assisted telephone interview in a two-stage stratified sample of adults living in households. RESULTS: 2,446 subjects were interviewed. The mean age was 39.8 years old. The majority was female and 42.7% had less than 10 years of education. The prevalence of CP was 28.1%. The independent factors associated with CP were female gender (OR = 2.0; p < 0.001), age older than 65 years (OR = 1.4; p = 0.019) and less than 15 years of education (OR = 1.3-1.6; p < 0.04). CONCLUSIONS: The prevalence of CP was high and similar to that which has been reported in developed countries. These results raise awareness about CP and may potentially help clinicians and policy makers to design better health care programs for CP treatment in these populations.

Prevalence of chronic pain in a metropolitan area of a developing country: a population-based study / Prevalência de dor crônica em área metropolitana de um país em desenvolvimento: um estudo populacional

ABSTRACT Objective To estimate the prevalence of chronic pain (CP) in the adult population living in the city of São Paulo, Brazil, and to identify factors associated with CP in developing countries. Methods A cross-sectional study using a computer-assisted telephone interview in a two-stage stratified sample of adults living in households. Results 2,446 subjects were interviewed. The mean age was 39.8 years old. The majority was female and 42.7% had less than 10 years of education. The prevalence of CP was 28.1%. The independent factors associated with CP were female gender (OR = 2.0; p < 0.001), age older than 65 years (OR = 1.4; p = 0.019) and less than 15 years of education (OR = 1.3-1.6; p < 0.04). Conclusions The prevalence of CP was high and similar to that which has been reported in developed countries. These results raise awareness about CP and may potentially help clinicians and policy makers to design better health care programs for CP treatment in these populations.

RESUMO Objetivo Estimar a prevalência de dor crônica (DC) na população adulta residente na cidade de São Paulo, Brasil, e assim identificar os fatores associados com DC em países em desenvolvimento. Método Estudo transversal utilizando entrevista por telefone auxiliada por computador em duas etapas numa amostra estratificada de adultos domiciliados em São Paulo. Resultados 2446 indivíduos foram entrevistados. A média de idade foi 39,8 anos. A maioria foi do sexo feminino e 42,7% tinham menos de 10 anos de escolaridade. A prevalência de DC foi de 28,1%. Os fatores independentes associados à DC foram gênero feminino (OR = 2,0; p < 0,001), idade superior que 65 anos (OR = 1,4; p = 0,019) e menor que 15 anos de escolaridade (OR = 1,3-1,6; p < 0,04). Conclusão A prevalência de DC foi alta e próxima à reportada em países desenvolvidos. Estes resultados irão auxiliar profissionais de saúde e gestores a realizarem programas de avaliação e tratamento de dor crônica mais ajustados à realidade local.

Revisão sistemática e metanálise do uso de procinéticos no refluxo gastroesofágico e na doença do refluxo gastroesofágico em Pediatria / Systematic review and meta-analysis of the use of prokinetics in gastroesophageal reflux and in gastroesophageal reflux disease in Pediatrics

OBJETIVO: Avaliar, por meio de revisão sistemática e metanálise, estudos randomizados que comparam os procinéticos domperidona, bromoprida, metoclopramida e betanecol ao placebo no tratamento do refluxo gastroesofágico (RGE) e da doença do refluxo gastroesofágico (DRGE) em crianças. MÉTODOS: BUsca bibliográfica de ensaios clínicos randomizados (Medline, EMBASE, Biological Abstracts, ISI/Web of Science, CINAHL, Lilacs e Cochrane). O desfecho primário foi eficácia na modificação dos sintomas de refluxo, conforme definição de autores das fontes primárias. Outras variáveis de interesse foram: complicações relacionadas ao RGE, alterações nos exames laboratoriais de controle, qualidade de vida, eventos adversos e abandono do tratamento. RESULTADOS: Foram incluídos quatro estudos com domperidona, dois com metoclopramida, um com betanecol. Nenhum estudo com bromoprida foi localizado. O risco de não resposta ao tratamento foi significativamente menor para os procinéticos quando comparados ao placebo (RR 0,35; IC95 por cento 0,14-0,88). A vantagem terapêutica individual em relação ao placebo se manteve para a domperidona (n=126; RR 0,27; IC95 por cento 0,14-0,52; NNT 3; I2 0 por cento) e betanecol (n=44, RR 0,19, IC95 por cento 0,05-0,55, NNT 2), mas não para metoclopramida (n=71; RR 0,63; IC95 por cento 0,07-5,71, I2 92,2 por cento). CONCLUSÕES: A evidência para o uso de procinéticos no RGE e na DRGE em crianças é limitada, pois os poucos estudos são ensaios preliminares de resposta em curto prazo e com limitações metodológicas.

OBJECTIVE: To evaluate, by systematic review and meta-analysis, randomized studies comparing the prokinetics (domperidone, bromopride, metoclopramide and bethanechol) to placebo in the treatment of gastroesophagic reflux (GER) and gastroesophagic reflux disease (GERD) in children. METHODS: Bibliographic search for randomized clinical trials (Medline, EMBASE, Biological Abstracts, ISI/Web of Science, CINAHL, Lilacs e Cochrane). The primary outcome was the modification of reflux symptoms. Other outcomes were: GER-related complications, alterations in control exams, life quality, adverse events and abandon of treatment. RESULTS: The metanalysis included four studies on domperidone, two on metoclopramide, and one on bethanechol. No study of bromopride was retrieved. The risk of non-response to the treatment was significantly smaller in children that received prokinetics in comparison to placebo (RR 0.35, 95 percentCI 0.14-0.88). Individual therapeutic advantage regarding placebo was related to domperidone (n=126; RR 0.27; 95 percentCI 0.14-0.52, NNT 3; I2 0 percent) and bethanechol (n=44; RR 0.19; 95 percentCI 0.05-0.55; NNT 2), but not to metoclopramide (n=71; RR 0.63; 95 percentCI 0.07-5.71; I2 92.2 percent). CONCLUSIONS: The evidence for prokinetic use in GER and GERD in children is limited because the few studies report preliminary trials that evaluate short-term responses and show methodological limitations.